MedTrace Logo

Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain

NCT00941746 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2011-06-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF).

Conditions

  • Osteoarthritis, Knee

Interventions

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

PG110

Single, slow intravenous infusion

BIOLOGICAL

Placebo

Single, slow intravenous infusion that matches PG110 in appearance

Sponsors & Collaborators

Principal Investigators

  • Jerry Hall, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00941746 on ClinicalTrials.gov